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Abstract 
Bone metastasis from endometrial cancer is rare. We report a case of endometrial cancer 
which was diagnosed by the presence of bone metastasis and treated with zoledronic 
acid. A 57-year-old woman complaining of progressive right hip pain consulted an 
orthopedist. She had no gynecologic complaints. X-rays revealed an osteolytic lesion of 
the right ischium. Bone scintigraphy was subsequently carried out and showed isotope 
accumulation in the right ischium. Computed tomography revealed an enlarged uterus; 
the patient consequently consulted a gynecologist. Histological sections of an 
endometrial biopsy showed endometrioid adenocarcinoma. Hysterectomy and bilateral 
salpingo-oophorectomy, as well as bone biopsy of the right ischium, were therefore 
carried out. A moderately differentiated endometrioid adenocarcinoma was expressed in 
the corpus. Histopathological examination of the bone biopsy also revealed 
adenocarcinoma. The final diagnosis was stage IVB endometrial cancer with bone and 
lung metastasis. Good pain relief was achieved due to chemotherapy. However, 2 
months after completion of the chemotherapy, the patient was administered zoledronic 
acid because her hip pain had gradually increased. Following zoledronic acid 
administration, the hip pain reduced. Radiotherapy was then given for the right ischial 
metastasis after the ninth course of zoledronic acid therapy because the metastasis site 
had increased and the possibility of a pathological fracture had risen. However, the 
patient died 21 months after the initial treatment because of disease progression. 
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Introduction 
Endometrial cancer is the most common malignancy of the female genital tract, and its 
incidence has increased remarkably. In Japan, the total number of endometrial cancer 
cases increased from 2,115 in 1994 to 4,267 in 2005 [1]. The first presenting symptom is 
commonly vaginal bleeding and most patients are at an early stage [2], resulting in a 
favorable overall survival rate. Endometrial cancer is more likely to metastasize to the 
lymph nodes, liver and lungs, while bone metastasis is very rare. Radiotherapy has been 
proven to play a palliative role in patients with bone metastases and administration of 
bisphosphonates, especially zoledronic acid, is used to prevent the symptoms of bone 
metastasis. 
We report a case of endometrial cancer which was diagnosed by the presence of bone 
metastasis and treated with zoledronic acid, and review the related literature. 
Case Report 
A 57-year-old Japanese woman consulted an orthopedist, complaining of progressive right hip pain 
over a period of 2 months and lower abdominal pain. She had no gynecologic complaints such as 
vaginal bleeding. She was gravida 3, para 3, and menstruation had ceased at 44 years of age. Her medical 
history indicated that she had undergone a total gastrectomy, followed by chemotherapy, for treatment 
of gastric cancer 4 years previously. X-rays revealed an osteolytic lesion on the right ischium. Bone 
scintigraphy was carried out and showed isotope (technetium TC99m) accumulation in the right 
ischium and right pubis. These findings suggested that the lesion was likely to be a bone metastasis of 
the gastric cancer. However, computed tomography revealed an enlarged uterus with swelling of the 
para-aortic nodes and multiple lung nodes, which prompted a gynecologic consultation. Consequently, 
she was referred to our hospital for a gynecologic examination. Magnetic resonance imaging showed 
enlargement of the uterus, with a mass measuring 3 × 4 cm in the endometrial cavity. The mass showed 
heterogeneous medium and high signal intensity on T2-weighted images, and swelling of the left ovary 
was observed. An endometrial biopsy was performed and subjected to histological examination. 
Hematoxylin and eosin-stained sections showed a well-differentiated endometrioid adenocarcinoma. 
She was therefore diagnosed with endometrial cancer. 
A hysterectomy, bilateral salpingo-oophorectomy and bone biopsy of the right ischium were carried 
out. Peritoneal cytology was negative. On pathological examination, a moderately differentiated 
endometrioid adenocarcinoma was expressed in the corpus and cervix of the uterus and left ovary. 
Histopathological examination of the bone biopsy revealed an adenocarcinoma that was CK7
+/CK20
– 
and ER
+/PR
+. The final diagnosis was stage IVB endometrial cancer with bone and lung metastases. The 
postoperative treatment consisted of paclitaxel (180 mg/m
2) plus carboplatin (AUC = 6) for 6 cycles, 
because of the multiple metastases. As a result, good pain relief was achieved and the other metastases 
became smaller. However, 2 months after completion of the chemotherapy, the hip pain gradually 
increased, and she was administered zoledronic acid for symptom relief of the bone metastasis. After 
receiving zoledronic acid, her hip pain gradually reduced. Radiotherapy was given for the right ischial 
metastasis (37.5 Gy/15 Fr) after the ninth course of zoledronic acid therapy because the metastasis site 
had increased and the possibility of a pathological fracture had risen. However, the patient died 21 
months after the initial treatment because of disease progression. 
Discussion 
Bone metastases are the most common malignant bone tumors, and their most 
common primary tumors are lung and breast cancers. Bone metastasis is rare in 
endometrial cancer, with a reported frequency of 0–8% [3, 4]. In an autopsy study, the 
corresponding frequency was 25–27% [5, 6] and the vertebrae were the most common  
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metastasis sites [5]. Bone metastasis is usually seen together with intra-abdominal and 
pelvic recurrences and/or other organ metastases. It is assumed that the mechanism of the 
vertebral metastasis involves Batson’s paravertebral valveless venous plexus [7]. It is also 
possible that the vascular invasion could start in the lymphatics, where tumor cells gain 
access to the venous return and then to the systemic circulation via arterial outflow [8, 9]. 
The reported cases in the English literature obtained in searches of the PubMed and 
ScienceDirect electronic databases up to June 2010 are presented in table 1 and table 2. 
Table 1 shows the diagnostic cases of bone metastasis after initial treatment of 
endometrial cancer. In the 31 cases, the average interval between the detection of the 
endometrial cancer and the bone metastasis varied from 1 to 148 months (median, 17 
months). A high incidence of bone metastasis with high-grade adenocarcinoma was 
revealed. All the patients complained of pain at the bone metastatic site, and the limbs 
and vertebrae were more frequently involved than the pelvis. Radiotherapy was frequently 
selected in the treatment of bone metastasis, and 18 patients died between 1 and 54 
months (median, 8.5 months) after detection of the bone metastasis. Table 2 shows cases 
in which the bone metastasis was simultaneously detected at the time of the diagnosis of 
endometrial cancer. In those 21 cases, the most common first presenting symptom was 
pain and only 2 had vaginal bleeding. A high incidence of bone metastasis with high-
grade adenocarcinoma was revealed, and showed the same pattern as the recurrence 
cases. Although the limbs were the most frequent metastatic sites, pelvic metastasis was 
more frequently observed in the initial diagnosis cases (33%) than in the recurrence cases 
(13%). This situation is considered to arise because the uterine tumors had stayed in the 
pelvis for a long time in the initial diagnosis cases. Radiotherapy was often selected in the 
treatment of bone metastasis. Ten patients died between 2 and 34 months (median, 9.5 
months) after diagnosis. Although the first presenting symptom is usually vaginal 
bleeding and most patients are at an early stage of endometrial cancer, the first presenting 
symptom in these cases was hip pain, not vaginal bleeding. Therefore, there might have 
been a delay before the patients consulted a physician at the hospital. 
In the present case, chemotherapy was chosen first because there were multiple distant 
metastases as well as the bone metastasis. As a result, the hip pain and tumor size were 
temporarily reduced. However, 2 months after completion of the chemotherapy, the hip 
pain had increased. The patient refused to receive further chemotherapy or hormone 
therapy. It has been reported that zoledronic acid may be effective for not only bone 
metastasis but also soft tissue organ metastases [10]. Therefore, only zoledronic acid was 
administered for pain relief. This case is the first report of administration of zoledronic 
acid for bone metastasis of endometrial cancer. Zoledronic acid was effective for the hip 
pain but could not suppress the growth of the bone metastasis. In this case, radiotherapy 
was not used concomitantly with zoledronic acid because of the multiple metastases. 
However, it has been reported that bisphosphonates seem to improve the clinical results 
obtained with radiotherapy in bone metastasis of renal cell carcinoma [11]. In our review, 
the median prognosis was 8–9 months’ survival time after diagnosis of bone metastasis. 
Our patient survived for 21 months after detection of the bone metastasis, and zoledronic 
acid as well as chemotherapy and radiotherapy might have contributed to this outcome. 
In conclusion, the present case involved bone metastasis from endometrial cancer, 
which is rare. Vaginal bleeding as the first symptom was absent, and consequently the 
disease was not detected until it had progressed to bone metastasis. In addition, this  
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report describes the use of zoledronic acid for bone metastasis of endometrial cancer for 
the first time. 
 
 
 
Table 1. The diagnostic cases of bone metastasis after initial treatment of endometrial cancer (n = 31) 
Case Age 
years 
Time to 
bone 
metas-
tasis 
months 
Histo- 
logy 
Stage  Site(s) of bone  
metastasis 
Other  
site(s) of  
metastasis 
Symptom(s) Treatment  Survival   
after  
bone 
metastasis 
months 
Dead 
or  
alive 
01 67  015 adeno  I  fibula    pain  RT  012 dead
02 59  009  G2  IC  femur  lung  pain, swelling  RT, chemo, HRT     
03 48  030  G2-G3  IIB  femur  lung  pain  RT, chemo, HRT  041 alive
04 77  024  G3  IC  metatarsus  lung  pain  amputation, RT, HRT  016 alive
05 86  018 SCC IIIC  hallux  lung  pain  amputation      dead
06 67  004   IC  tibia,  femur, 
metatarsus 
 pain  RT    002 dead
07 66  018 G3  IA  humerus    pain  RT,  HRT  024 alive
08 45  036 G2  IA  cranium  lung  swelling  surgery,  RT  006 dead
09 55  018 adeno    calcaneus,  talus  lung  pain  RT  036 alive
10 55  024 G2  IB  calcaneus      pain  RT  010 alive
11 87  108      sternum    pain  surgery  060 alive
12 67  060 adeno  IVB mandibula  lung,  kidney  pain,  swelling  surgery    dead
13 51  001 G3  IIIC  humerus  lymph  node  pain  RT  006 alive
14 61    G1  IIIB  calcaneus    pain       
15 81  036 adeno  IIB calcaneus    pain  RT     
16 70  024 G3  IC  ischium    pain  chemo,  pamidronate  036 alive
17 61  044  G1  IIIA  vertebrae  any   pain  RT, surgery  012 dead
18 65  003  adeno  IIIB  vertebrae, rib  any   pain  chemo  009 dead
19 58  010  adeno  IA  L4, L5    pain  RT, surgery, chemo  199  alive
20 70  010  G3  IIB  vertebrae, rib, parietal   any   pain  RT  002 dead
21 65  007  G1  IIIB  tibia, femur   any   pain  RT, surgery  042 dead
22 55  025  adeno    pelvis, vertebrae, rib  any   pain  chemo  007 dead
23 60  012  clear    humerus, clavicle    pain  surgery, RT, chemo  013 dead
24 71  016  G2  IVB  L1, L3, L4  any   pain    001 dead
25 74  008  adeno  IB  vertebrae, rib  any   pain  RT, chemo  005 dead
26 62  011 G2  IIIC  calvarium,  femur, 
spine 
any   pain  surgery   054 dead
27 60  003  G3  IVB  sacroiliac joint  any   pain  RT, chemo  008 dead
28  52  148      vertebrae  any   pain  surgery   007 dead
29 55  009  G3  IIIC  rib, femur, spine    pain  RT, surgery  026 dead
30 40  003 G3  IIIC  ischium    pain  chemo  010 dead
31 56  026  G2  IC  femur  any   pain  surgery, chemo  012 alive
adeno = Adenocarcinoma; SSC = squamous cell carcinoma; RT = radiotherapy; HRT = hormone replacement therapy; chemo = 
chemotherapy. 
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Table 2. Cases of bone metastasis detected simultaneous with diagnosis of endometrial cancer (n = 21) 
Case Age 
years 
Histology  Site(s) of bone metastasis  Other site(s) of  
metastasis 
Symptom(s) Treatment Survival  after 
bone metastasis 
months 
Dead or 
alive 
01  54  adeno  fibula    pain  RT, HRT, cordotomy  29  dead 
02  61  G1  calcaneus, talus    pain, swelling  surgery, chemo, HRT  14  alive 
03   G1  ischium    pain  RT  48  alive 
04 71  G3  mandibula    bleeding  RT,  chemo  14  alive 
05  44  G2  femur    pain  surgery, RT, chemo  24  alive 
06  59  G2  calcaneus    pain  RT, chemo, HRT  60  alive 
07 73  G3  tibia    pain  chemo  09 dead 
08 51  G3  cervical  vertebra    bleeding  chemo  02 dead 
09 70  G1  tibia    pain  RT,  chemo  47  alive 
10 64  CS  tibia    pain  RT  06 dead 
11 39  G2  ischium    pain  surgery,  RT  36  alive 
12  63  G1  thoracic vertebra    unable to walk  surgery, RT  60  alive 
13 76  G3  calcaneus    pain  chemo  19  dead 
14 57    tibia  lung,  kidney    RT     
15  67  G1  calcaneus, talus, metatarsal    pain  surgery  20  alive 
16  55  G3  ischium, acetabulum, femur    pain  RT, surgery  10  dead 
17  47  G2  vertebrae, acetabulum, femur, 
humerus 
 pain  chemo  07 dead 
18 62  G3  vertebrae  any  pain  RT,  chemo  16  dead 
19  32  G3  pubic rami, acetabulum    pain  RT, chemo  05 alive 
20  84  G2  ischium, superior ramus, 
acetabulum 
 pain  RT  34  dead 
21  77  G3  inferior pubic ramus, sacrum, 
acetabulum 
any pain  RT,  chemo  08 dead 
adeno = Adenocarcinoma; RT = radiotherapy; HRT = hormone replacement therapy; chemo = chemotherapy. 
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